List of Excipients in Branded Drug CINACALCET HYDROCHLORIDE

Generic Drugs Containing CINACALCET HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Amneal Pharmaceuticals LLC	cinacalcet	65162-155	CELLULOSE, MICROCRYSTALLINE
Amneal Pharmaceuticals LLC	cinacalcet	65162-155	CROSPOVIDONE
Amneal Pharmaceuticals LLC	cinacalcet	65162-155	D&C YELLOW NO. 10
Amneal Pharmaceuticals LLC	cinacalcet	65162-155	FD&C BLUE NO. 2

What are the Most Frequently-Used Excipients in CINACALCET HYDROCHLORIDE?

# Of NDCs	Excipient
2	CELLULOSE, MICROCRYSTALLINE
2	CROSPOVIDONE
1	D&C YELLOW NO. 10
2	FD&C BLUE NO. 2

Cinacalcet Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

Cinacalcet hydrochloride is an immediate-release oral calcimimetic with established generic competition and limited protection from the original Sensipar patent estate. The strongest commercial opportunities are formulation-led: improving dissolution, reducing food-effect variability, enabling lower-cost manufacturing, and developing patient-friendly dosage forms for chronic dialysis and secondary hyperparathyroidism treatment.

Excipient selection is commercially important because cinacalcet hydrochloride has low aqueous solubility, a clinically relevant food effect, and chronic-use adherence requirements. Generic products must match the reference product's performance while controlling tablet weight, dissolution, stability, taste, and manufacturing cost.

What is cinacalcet hydrochloride used for?

Cinacalcet hydrochloride is approved for:

• Secondary hyperparathyroidism in adults with chronic kidney disease receiving dialysis.
• Hypercalcemia in adults with parathyroid carcinoma.
• Hypercalcemia in adults with primary hyperparathyroidism who cannot undergo parathyroidectomy or for whom surgery is clinically inappropriate.

Sensipar, Amgen's reference product, is supplied as 30 mg, 60 mg, and 90 mg tablets. The product is administered orally and should be taken with food or shortly after a meal. The FDA label states that food increases cinacalcet exposure, making fed-state administration relevant to both clinical use and bioequivalence strategy.[1]

Cinacalcet hydrochloride is a small-molecule drug rather than a biologic. Biosimilar regulation does not apply. Competitive products are generally filed through the abbreviated new drug application pathway.

What are the key physicochemical challenges for cinacalcet hydrochloride?

The principal formulation challenge is inadequate aqueous solubility. Cinacalcet hydrochloride requires excipient and process engineering to produce reliable dissolution across the gastrointestinal environment.

Formulation-relevant properties

Attribute	Commercial formulation implication
Active ingredient	Cinacalcet hydrochloride
Dosage form	Immediate-release tablet
Solubility profile	Requires dissolution enhancement and particle-control strategy
Food effect	Fed administration increases exposure
Dose strengths	30 mg, 60 mg, and 90 mg reference strengths
Treatment duration	Often chronic, increasing adherence and tolerability requirements
Primary markets	United States, Europe, Japan, emerging generic markets
Regulatory route	ANDA or corresponding national generic pathway
Biosimilar exposure	None

Cinacalcet tablets also present a dose-size problem. The 30 mg strength can contain a relatively high proportion of excipients compared with active pharmaceutical ingredient. This increases sensitivity to blend uniformity, segregation, lubrication, and compression behavior.

The 60 mg and 90 mg strengths create a separate scaling challenge. A formulation that performs well at 30 mg may not maintain equivalent dissolution, hardness, friability, and tablet dimensions at higher strengths.

Which excipients are used in Sensipar tablets?

The Sensipar label identifies a conventional immediate-release tablet system. Listed inactive ingredients include lactose monohydrate, pregelatinized starch, povidone, crospovidone, colloidal silicon dioxide, magnesium stearate, hypromellose, talc, titanium dioxide, and colorants depending on strength.[1]

Functional role of the reference excipients

Excipient class	Likely formulation function
Lactose monohydrate	Diluent and tablet mass builder
Pregelatinized starch	Binder and disintegration support
Povidone	Binder
Crospovidone	Superdisintegrant
Colloidal silicon dioxide	Glidant and flow aid
Magnesium stearate	Lubricant
Hypromellose	Film-coating polymer
Talc	Anti-tacking and coating aid
Titanium dioxide and colorants	Product identification and appearance

The reference formulation provides a practical benchmark, but an ANDA applicant does not need to copy every excipient. A generic formulation must satisfy quality, bioequivalence, stability, and performance requirements. Excipients can be substituted if the final product meets applicable regulatory standards.

What excipient strategies can improve cinacalcet dissolution?

The most relevant strategy is to increase the rate and consistency of drug release without converting the product into a modified-release dosage form.

Particle-size reduction

Micronization can increase surface area and improve dissolution. The commercial limitation is that smaller particles may have poor flow, high cohesiveness, electrostatic behavior, and greater segregation risk. A glidant system and controlled granulation process may be required.

Particle engineering is most attractive where the manufacturer can reduce dissolution variability without adding a complex excipient system. It can also reduce dependence on large quantities of surfactant or polymer.

Wet granulation

Wet granulation can improve blend uniformity and compressibility, particularly for low-dose or poorly flowing blends. The process must control granule size and residual moisture. Excessive granulation can delay disintegration and dissolution by creating dense granules.

A water-based process may be preferred for cost and safety, but solvent selection and drying conditions must be assessed against polymorphic stability and degradation risk.

Superdisintegrant optimization

Crospovidone, croscarmellose sodium, and sodium starch glycolate can be screened for disintegration and dissolution performance. Crospovidone is particularly relevant where rapid liquid uptake and reduced gel formation are desirable.

The commercial opportunity is not simply to maximize disintegrant concentration. Excessive levels can reduce tablet strength, increase friability, or alter powder flow. Intra-granular and extra-granular addition can produce different release profiles.

Wetting and surfactant systems

Sodium lauryl sulfate and poloxamers may improve wetting of hydrophobic drug particles. Surfactants must be used cautiously because they can affect taste, gastrointestinal tolerability, tablet robustness, and dissolution in ways that complicate scale-up.

A surfactant-based strategy is more defensible when it produces a measurable improvement under discriminatory dissolution conditions. A small amount of surfactant may provide greater value than a high-polymer solid dispersion for a conventional immediate-release generic.

Amorphous solid dispersions

Polyvinylpyrrolidone, copovidone, hypromellose, and hypromellose acetate succinate can stabilize an amorphous drug form and improve apparent solubility. This approach can deliver stronger dissolution performance, but it increases development and manufacturing complexity.

The main risks are:

• Recrystallization during storage.
• Moisture sensitivity.
• Higher process cost.
• More difficult scale-up.
• Need for stronger solid-state characterization.
• Potential mismatch between rapid in vitro dissolution and in vivo exposure.

For a mature generic market, an amorphous solid dispersion is commercially justified only if it supports a meaningful product advantage, such as a smaller tablet, improved fed/fasted consistency, or an alternative dosage form.

What formulations are protected or commercially differentiated for cinacalcet?

The original commercial product is an immediate-release film-coated tablet. The core patent estate around cinacalcet has largely expired, and the principal opportunity is now formulation differentiation rather than basic composition-of-matter exclusivity.

Potential differentiated products include:

• Orally disintegrating tablets for patients with dysphagia.
• Mini-tablets or multiparticulates for administration flexibility.
• Taste-masked granules or sprinkle formulations.
• Lower-pill-burden dosage forms.
• Improved dissolution tablets with reduced food-effect variability.
• Unit-dose packaging for dialysis-center distribution.
• Pediatric or geriatric presentations, subject to regulatory and clinical requirements.

Any product that departs from the reference dosage form may require more extensive development. An orally disintegrating or sprinkle product may raise questions about dose uniformity, palatability, administration with soft food, stability after opening, and comparative bioavailability.

When does cinacalcet lose exclusivity?

Cinacalcet has already lost the principal U.S. market exclusivity associated with Sensipar. FDA-approved generic competition entered the U.S. market after expiration of the key patent and related regulatory protections.

The U.S. Orange Book identifies listed patents and regulatory exclusivity for approved products. The commercial relevance of each listed patent depends on its expiration date, pediatric extensions, litigation history, and whether the patent is challenged in an ANDA Paragraph IV certification.[2]

U.S. exclusivity position

Protection category	Current commercial position
New chemical entity exclusivity	Expired
Original composition-of-matter protection	Expired
Reference-product market exclusivity	Expired
Generic entry	Established
Biosimilar pathway	Not applicable
Remaining opportunity	Formulation, manufacturing, geographic, and service differentiation

Patent expiry does not eliminate all legal risk. Later patents may cover specific formulations, manufacturing processes, salts, polymorphs, dosing regimens, or methods of treatment. Those claims must be reviewed individually by jurisdiction and product configuration.

What is the Orange Book status of cinacalcet?

Cinacalcet's U.S. reference product is Sensipar, NDA 021688. The FDA Orange Book is the controlling source for listed patents, therapeutic-equivalence ratings, and current patent information.[2]

For commercial diligence, the relevant review should include:

1. Current Orange Book listings for Sensipar.
2. Approved ANDAs and therapeutic-equivalence codes.
3. Patent certifications submitted by generic applicants.
4. FDA approval dates for competing strengths.
5. Any listed patents associated with later approved indications or dosage forms.
6. Litigation records under the Hatch-Waxman framework.

Because Orange Book entries and approved applications can change, a transaction or launch decision should rely on the current FDA database rather than historical patent summaries.

Which companies are challenging or competing with Sensipar?

The U.S. market has generic cinacalcet hydrochloride products from multiple manufacturers. Generic competition has included major suppliers such as Teva, Amneal, Cipla, and other ANDA holders, depending on strength, market period, and distribution status.

Competition is primarily based on:

• Acquisition cost.
• Reliable supply.
• FDA-approved therapeutic equivalence.
• Tablet appearance and packaging.
• Distribution into dialysis networks.
• Contracting with wholesalers and specialty channels.
• Manufacturing cost per tablet.

The market is structurally exposed to price erosion because the product is a conventional small-molecule tablet with multiple potential suppliers. A new entrant needs either a cost advantage, differentiated supply reliability, a dosage-form improvement, or access to a defensible geographic market.

What Paragraph IV challenges affected cinacalcet?

Paragraph IV certifications are used when an ANDA applicant asserts that a listed patent is invalid, unenforceable, or not infringed. For cinacalcet, Paragraph IV activity was relevant before generic entry and contributed to the timing of market competition.

The business impact of a Paragraph IV filing depends on:

• The specific patent challenged.
• The timing of the ANDA notification.
• Whether the patent holder filed suit within the statutory period.
• The availability of 180-day generic exclusivity.
• The strength of infringement and validity positions.
• Any settlement agreement or authorized-generic arrangement.

Historical Paragraph IV events should not be treated as continuing barriers after patent expiry. The present decision standard is the current Orange Book and court record.

How strong is the cinacalcet patent estate?

The original cinacalcet estate is commercially weak as a barrier to ordinary generic entry because the primary exclusivity period has ended and multiple generics are available.

Patent-strength assessment

Patent category	Barrier strength for standard generic
Original active-ingredient patent	Low after expiration
Basic immediate-release tablet claims	Low to moderate, depending on surviving claims
Narrow formulation claims	Moderate if technically distinct and enforceable
Manufacturing-process claims	Moderate where process is difficult to design around
Method-of-use claims	Variable, depending on indication and claim scope
ODT or taste-masked claims	Potentially meaningful for differentiated products
Foreign patents	Highly jurisdiction-specific

A formulation patent has greater commercial value when it protects a clinically relevant feature rather than an easily substituted excipient combination. Claims directed to a defined dissolution profile, stabilized amorphous form, particle-size distribution, or manufacturing process may offer stronger practical protection than broad claims covering routine tablet ingredients.

What commercial opportunities exist for cinacalcet excipients?

The largest opportunity is not a new excipient molecule. It is a high-performing excipient system that reduces total product cost or solves a specific formulation problem.

High-value opportunities

Direct-compression platforms

A directly compressible lactose, mannitol, microcrystalline cellulose, or co-processed excipient system could reduce processing steps. The product must maintain content uniformity and dissolution across all three strengths.

Co-processed excipients

Co-processed fillers and disintegrants can improve flow, compressibility, and tablet robustness. Their value increases where manufacturers want to avoid wet granulation or reduce compression force.

Taste-masking systems

Taste masking is commercially relevant for orally disintegrating, chewable, sprinkle, or liquid-adjacent presentations. Cinacalcet's bitterness makes polymer coatings, ion-exchange resins, lipid barriers, and multiparticulate systems potential development areas.

Low-moisture excipient systems

A low-moisture formulation can improve stability where the drug or amorphous intermediate is moisture-sensitive. Packaging and excipient selection should be considered together.

Functional film coatings

Film coatings can improve swallowability, product identification, light protection, and dose-strength differentiation. Coating systems must avoid delaying release or creating defects during high-speed production.

Dialysis-channel packaging

Unit-dose blistering and calendar packaging can support controlled distribution through dialysis centers and improve medication handling. Packaging is not an excipient opportunity, but it can increase the commercial value of a stable tablet platform.

How does cinacalcet compare with competing calcimimetics?

Cinacalcet competes clinically with etelcalcetide, an injectable calcimimetic used in adults with secondary hyperparathyroidism receiving hemodialysis. Cinacalcet has the advantages of oral administration and established generic availability. Etelcalcetide has administration by intravenous injection at the end of hemodialysis, which can reduce reliance on patient self-administration but requires an injectable delivery setting.[3]

Factor	Cinacalcet hydrochloride	Etelcalcetide
Modality	Oral small molecule	Injectable peptide
Generic or biosimilar exposure	Generic competition	Biologic competition is more complex
Excipient opportunity	High for tablets and patient-friendly forms	Parenteral formulation constraints
Adherence issue	Daily oral administration	Dialysis-center administration
Manufacturing barrier	Moderate	Higher biologic and sterile-manufacturing burden
Price pressure	High from generics	More dependent on biologic contracting

The comparison supports a focused commercial thesis: cinacalcet formulation innovation must address adherence, tolerability, administration convenience, or cost. A marginally different tablet with no measurable benefit is unlikely to command durable pricing.

What generic launch risks exist for cinacalcet?

Generic launch risk is concentrated in regulatory execution and commercial economics rather than basic patent blockage.

Key risks include:

• Failure to match fed-state exposure.
• Dissolution variability between strengths.
• Inadequate stability under high humidity.
• Poor tablet robustness during packaging and shipping.
• Taste or swallowing problems in an alternative dosage form.
• Excessive manufacturing cost from complex solid-state processing.
• Price erosion after multiple ANDA approvals.
• Concentrated buyer power in dialysis distribution.
• Supply interruptions caused by a limited API or excipient source.

An excipient supplier can reduce risk by providing compendial documentation, global regulatory support, multiple manufacturing sites, extractables and leachables data where relevant, and consistent particle-size specifications.

What manufacturing and intellectual-property barriers remain?

The active pharmaceutical ingredient is broadly available, but commercial-scale production still requires control of impurity profiles, particle size, polymorphic state, residual solvents, and batch consistency.

The most defensible manufacturing barriers may involve:

• High-throughput granulation with controlled dissolution.
• Stable amorphous drug dispersion.
• Taste-masked multiparticulates.
• Consistent low-dose blend uniformity.
• Continuous manufacturing.
• Robust coating at commercial scale.
• A validated process that supports three strengths with limited line changeover.

Process patents can protect these features, but their value depends on whether competitors can obtain equivalent performance through a different process. A process that is expensive to prove or difficult to detect may have limited enforcement value even if technically valid.

Key Takeaways

• Cinacalcet hydrochloride is a mature generic small-molecule market with limited basic patent protection remaining.
• The primary formulation challenge is controlling dissolution for a poorly soluble drug with a clinically relevant food effect.
• Reference-product excipients include lactose, pregelatinized starch, povidone, crospovidone, colloidal silicon dioxide, magnesium stearate, hypromellose, talc, titanium dioxide, and colorants.
• Commercially attractive excipient strategies include particle engineering, superdisintegrant optimization, direct compression, taste masking, and moisture control.
• Orally disintegrating, sprinkle, mini-tablet, and other patient-friendly presentations offer greater differentiation than a routine tablet substitution.
• The main generic risks are bioequivalence, dissolution, stability, supply reliability, and price erosion.
• Formulation and manufacturing patents may still matter for differentiated products, but ordinary immediate-release generic entry faces a substantially lower patent barrier.
• Excipient suppliers should compete on process performance, documentation, global supply continuity, and measurable product advantages.

FAQs About Cinacalcet Hydrochloride Excipient and Commercial Strategy

Is cinacalcet hydrochloride a good candidate for an orally disintegrating tablet?

Yes. Chronic dialysis patients may experience swallowing difficulty or high pill burden. An orally disintegrating tablet could create differentiation, but taste masking, dose uniformity, moisture control, and comparative bioavailability are central development requirements.

Which excipient is most important for cinacalcet dissolution?

No single excipient determines performance. Particle size, wetting, granulation, superdisintegrant selection, lubricant level, and compression force interact. A controlled formulation and process design is more valuable than simply increasing one disintegrant or surfactant.

Can a generic manufacturer use different excipients from Sensipar?

Yes, subject to applicable FDA requirements. The generic product must meet quality, bioequivalence, stability, labeling, and performance standards. Excipient changes are most defensible when they do not introduce new safety concerns or alter clinical performance.

Does cinacalcet have biosimilar competition?

No. Cinacalcet hydrochloride is a chemically synthesized small molecule. Competing products are generics, not biosimilars.

Is a cinacalcet formulation patent commercially valuable?

It can be valuable if it protects a difficult-to-design-around feature such as a validated dissolution profile, stable solid-state form, taste-masked system, or clinically useful alternative dosage form. Broad claims covering routine tablet excipients are generally less defensible in a mature generic market.

References

1. U.S. Food and Drug Administration. (2023). Sensipar (cinacalcet hydrochloride) prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2017). Parsabiv (etelcalcetide) prescribing information.